(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 31 December 2003 (31.12.2003)

PCT

(10) International Publication Number WO 2004/000094 A2

(51) International Patent Classification7:

A61B

(21) International Application Number:

PCT/US2003/012739

(22) International Filing Date: 24 April 2003 (24.04.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/389,795 19 June 2002 (19.06.2002) US 60/432,811 11 December 2002 (11.12.2002) US 60/432,943 11 December 2002 (11.12.2002) US 60/451,978 3 March 2003 (03.03.2003) US

(71) Applicant (for all designated States except US): **SMITHKLINE** BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19101 (US).

[US/US]; One Franklin Plaza, Philadelphia, PA 19101 (US).

(72) Inventors; and (75) Inventors/Applicants (for US only): BACUS, Sarah, S. [US/US]; c/o Ventana Medical Systems, Inc., 1910 Innovation Park Drive, Tuscon, AZ 85737 (US). HERRLE, Myra, R. [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). KIRK, L., Edward [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). SPECTOR, Nell, L. [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). STOCUM, Michael, T. Triangle Park, NC 27709 (US). STOCUM, Michael, T. (54) Title: PREDICTIVE MARKERS IN CANCER THERAPY

(55) Abstract: Molecular markers useful in medicine response test

[US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). XIA, Wenle [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

- (74) Agents: LEVY, David, J. et al.; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(57) Abstract: Molecular markers useful in medicine response tests are provided, as an aid in determining whether an individual subject s tumor is responding to treatment with EGF and/or erbB2 inhibitors. Markers include phosphorylated ERK protein.